Why is McKesson stock rallying today?

McKesson shares rose nearly 4% after it extended its CVS Health supply agreement through June 2032, securing business that represents roughly 25% of consolidated revenue. The company also reaffirmed FY2027 adjusted EPS guidance of $44.20-$45.00 and its long-term adjusted EPS growth target of 13%-16% annually. The stock reached $924.21 intraday versus a prior close of $853.81, outperforming a broadly weaker market.

Analysis

The valuation implication is larger than the revenue retention itself: removing a binary customer-concentration overhang supports a lower equity-risk premium and makes MCK’s long-duration earnings algorithm more investable. The incremental benefit should accrue primarily through multiple durability rather than a material near-term EPS step-up, since large-chain distribution contracts are typically low-margin and can consume working capital. Cencora (COR) and Cardinal Health (CAH) are second-order losers only at the margin: a major addressable contract is effectively removed from the next competitive bidding cycle, reinforcing the distributors’ oligopolistic customer lock-in.

CVS gains operational continuity and avoids potentially costly inventory, systems, and specialty-pharmacy transition risk, but this does little to resolve the factors that dominate CVS’s equity value: Medicare Advantage cost trends, reimbursement pressure, leverage reduction, and retail pharmacy profitability. Accordingly, MCK/CVS relative performance should persist over the next 1-3 months if MCK confirms that contract economics, volume expectations, and cash conversion are unchanged at its next earnings update; CVS should not receive a comparable rerating.

The contrarian point is that a contract renewal removes downside rather than creating new earnings power. At a premium earnings multiple, MCK needs to sustain its 13-16% adjusted EPS framework through mix, specialty growth, and buybacks; any evidence that the renewed business carries lower spreads or worse receivable/inventory terms would cap upside despite retained revenue. Watch operating-cash-flow conversion and FY27 EPS guidance rather than headline revenue as the decisive proof points over the next two quarters.

Key Decisions for Investors

• Accumulate MCK on pullbacks toward the pre-announcement trading range rather than chase a gap-up; target a 3-6 month 8-12% total-return outcome from de-risking and continued EPS execution, with a stop/review if FY27 adjusted EPS guidance falls below $44.20 or cash conversion weakens materially.
• Express the fundamental divergence through long MCK / short CVS in equal dollar amounts for 3-6 months. MCK has a company-specific execution catalyst, while CVS remains exposed to managed-care utilization and reimbursement revisions; exit if CVS demonstrates a credible improvement in Medicare Advantage margins or MCK discloses adverse contract economics.
• Do not initiate a broad long in CAH or COR on perceived distribution-sector sympathy. The news marginally strengthens incumbent scale advantages but provides no read-through on their own customer pricing, specialty mix, or litigation-related valuation drivers.
• Set an alert for MCK’s next quarterly disclosure of gross-margin rate, operating cash flow, and working-capital use. A retained volume base accompanied by lower margin or elevated inventory/receivables would invalidate the multiple-expansion thesis even if revenue remains intact.